We are the Faculty of Medicine & Dentistry at the University of Alberta, one of the world’s elite academic health sciences centres, where top students are taught by award-winning educators and mentored by renowned scientists in a dynamic learning environment.

We conduct our teaching, research and patient care in accordance with the highest international standards. We work with our partners in education, research and health care for the greater good of the local, regional and global community.

Outstanding areas of medical research at the University of Alberta include diabetes, obesity, virology, heart disease, motor control and rehabilitation, protein structure and function, and transplantation.

Department of Oncology

Division of Medical Oncology

About Me

I direct the Clinical Trial Unit at the Cross Cancer Institute, a highly motivated team of investigators and experienced staff that treats approximately 15% of our patients on cancer therapy trials. I am Executive Director of Translational Research in Oncology (www.trioncology.org), a global network of academic investigators testing new anticancer drug treatments. I serve on the steering committees of seven international drug trials.

I Chair the Alberta Pre-Phase 1 Cancer Program (www.prephaseone.com) that brings Alberta-made anticancer compounds to first-in-human testing, and work with academic collaborators to bring their ideas to the clinic. My translational research program focuses on developing tests to predict which patients are most likely to benefit from anticancer therapy, and exploiting novel targets and pathways to improve systemic cancer therapy.

My research program is funded by the Alberta Cancer Foundation, the Canadian Breast Cancer Research Alliance, the US Department of Defense, and multiple industry sponsors.

Research Facilities and AffiliationsMy primary academic appointment is in the Division of Medical Oncology in the Department of Oncology. I also hold a cross appointment in the Division of Experimental Oncology.

Expression and function of hexose transporters GLUT1, GLUT2, and GLUT5 in breast cancer-effects of hypoxia.

Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy.

Faculty Contact Information

Our fax number may be used for academic matters only. Contact information for a physician’s clinical practice should be obtained from the CPSA website or the Alberta Referral Directory. In accordance with privacy legislation, no identifiable health information should be sent to the Dean’s Office.